Related references
Note: Only part of the references are listed.An Unsupported Preference for Intravenous Antibiotics
Ho Kwong Li et al.
PLOS MEDICINE (2015)
A randomized controlled clinical trial of levofloxacin 750 mg versus 500 mg intravenous infusion in the treatment of community-acquired pneumonia
Xu Zhao et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2014)
A tailored implementation strategy to reduce the duration of intravenous antibiotic treatment in community-acquired pneumonia: a controlled before-and-after study
M. F. Engel et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2014)
Using Highly Detailed Administrative Data to Predict Pneumonia Mortality
Michael B. Rothberg et al.
PLOS ONE (2014)
Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI)
Ilija Kuzman et al.
BMC PULMONARY MEDICINE (2014)
Does Empirical Therapy with a Fluoroquinolone or the Combination of a β-Lactam Plus a Macrolide Result in Better Outcomes for Patients Admitted to the General Ward?
Joerg Ruhe et al.
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2013)
Switch therapy in hospitalized patients with community-acquired pneumonia: Tigecycline vs. Levofloxacin
Julio A. Ramirez et al.
BMC INFECTIOUS DISEASES (2012)
Levofloxacin for the treatment of respiratory tract infections
Antoni Torres et al.
EXPERT OPINION ON PHARMACOTHERAPY (2012)
Guidelines for the management of adult lower respiratory tract infections - Full version
M. Woodhead et al.
CLINICAL MICROBIOLOGY AND INFECTION (2011)
Fluoroquinolones in Community-Acquired Pneumonia Guide to Selection and Appropriate Use
Christopher R. Frei et al.
DRUGS (2011)
Implementation of guidelines for sequential therapy with fluoroquinolones in a Belgian hospital
Franky Buyle et al.
PHARMACY WORLD & SCIENCE (2010)
Use of Stabilized Inverse Propensity Scores as Weights to Directly Estimate Relative Risk and Its Confidence Intervals
Stanley Xu et al.
VALUE IN HEALTH (2010)
Economic benefit of a 1-day reduction in hospital stay for community-acquired pneumonia (CAP)
C.M. Kozma et al.
JOURNAL OF MEDICAL ECONOMICS (2010)
Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: A US-based study
C. R. Frei et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Outcomes of early switching from intravenous to oral antibiotics on medical wards
Dominik Mertz et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Early Switch to Oral Treatment in Patients with Moderate to Severe Community-Acquired Pneumonia A Meta-Analysis
Zoe Athanassa et al.
DRUGS (2008)
Implication of Clinical Pathway Care for Community-Acquired Pneumonia in a Community Hospital: Early Switch from an Intravenous beta-lactam Plus a Macrolide to an Oral Respiratory Fluoroquinolone
Yuichiro Shindo et al.
INTERNAL MEDICINE (2008)
Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults
Lionel A. Mandell et al.
CLINICAL INFECTIOUS DISEASES (2007)
Evaluation of an antibiotic intravenous to oral sequential therapy program
AI Pablos et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2005)
Efficacy of exclusively oral antibiotic therapy in patients hospitalized with nonsevere community-acquired pneumonia: A retrospective study and meta-analysis
TK Marras et al.
AMERICAN JOURNAL OF MEDICINE (2004)
Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia
V Erard et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2004)
Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia
JB Wasserfallen et al.
EUROPEAN RESPIRATORY JOURNAL (2004)
Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: A randomized, open-label, multicenter study of clinical efficacy and tolerability
H Lode et al.
CLINICAL THERAPEUTICS (2002)
Early switch and early discharge strategies in patients with community-acquired pneumonia - A meta-analysis
DC Rhew et al.
ARCHIVES OF INTERNAL MEDICINE (2001)
Share Paper
